Owners report satisfaction and perceived improvement following Sn-117m radiosynoviorthesis in dogs with osteoarthritis.

Sn-117m RSO demonstrates perceived sustained clinical benefit for canine OA with high owner satisfaction.

This multicenter survey evaluated owner satisfaction with Sn-117m radiosynoviorthesis (RSO) for canine osteoarthritis. Among 168 respondents (42.3% response rate), 63.1% reported satisfaction or high satisfaction. Clinically meaningful improvements were observed: 71.5% of dogs showed decreased OA interference with daily activities, with median improvement of one category among all responders and two categories among those improving. Pain perception improved in 78.6% after initial treatment, 82.9% after second treatment, and 83% after third treatment. Among 35 dogs receiving multiple treatments, 81% of owners reported comparable or greater improvement with subsequent doses. Treatment-related concerns were minimal (6.5%). Clinical outcome was identified as the primary satisfaction driver (68% rated very influential), significantly outweighing cost, anesthesia concerns, and other factors. Results suggest Sn-117m RSO provides repeatable, clinically important improvements in pain and function for dogs with osteoarthritis, with high owner satisfaction sustained across multiple treatments.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.